Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

ClinicalTrials.gov ID: NCT01179217

Public ClinicalTrials.gov record NCT01179217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this research is to evaluate the effects of L-glutamine as a therapy for Sickle Cell Anemia or Sickle ß0 Thalassemia as evaluated by the number of occurrences of sickle cell crises.

Study identification

NCT ID
NCT01179217
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Emmaus Medical, Inc.
Industry
Enrollment
230 participants

Conditions and interventions

Eligibility (public fields only)

Age range
5 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2010
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update posted
Aug 18, 2020

2010 – 2014

United States locations

U.S. sites
31
U.S. states
21
U.S. cities
26
Facility City State ZIP Site status
University of South Alabama Medical Center Mobile Alabama 36617
Phoenix Children's Hospital Center for Cancer and Blood Disorders Phoenix Arizona 85016
Kaiser Permanente Inglewood California 90301
Children's Hospital & Research Center at Oakland Oakland California 94609
Children's Hospital of Orange County Orange California 92868
Harbor-UCLA Medical Center Torrance California 90509
University of Denver School of Medicine Sickle Cell Treatment & Research Center Aurora Colorado 80045
Howard University Hospital & Howard University Washington D.C. District of Columbia 20060
University of Florida Gainesville Florida 32610-0296
All Children's Hospital St. Petersburg Florida 33701
Children's Healthcare of Atlanta at Egleston/Emory University Atlanta Georgia 30322
University of Illinois at Chicago Chicago Illinois 60612
University of Louisville School of Medicine Louisville Kentucky 40202
Sickle Cell Center of S. Louisiana, Tulane University School of Medicine New Orleans Louisiana 70112
Johns Hopkins University Baltimore Maryland 21205
Boston University Medical Center Boston Massachusetts 02118
Children's Hospital of Michigan Detroit Michigan 48201
University of Mississippi Medical Center Jackson Mississippi 39216
Children's Mercy Hospitals and Clinics Kansas City Missouri 64108
Children's Specialty Center of Nevada Las Vegas Nevada 89109
Comprehensive Cancer Center of Nevada Las Vegas Nevada 89109
Cooper University Hospital Camden New Jersey 08103
The Brooklyn Hospital Center Brooklyn New York 11201
SUNY - Downstate Medical Center Brooklyn New York 11203
Brookdale University Hospital and Medical Center Brooklyn New York 11212
New York Methodist Hospital - SC/Thalassemia Program Brooklyn New York 11215
Interfaith Medical Center Brooklyn New York 11238
Bronx Lebanon Hospital The Bronx New York 11203
Presbyterian Blume Pediatric Hematology-Oncology Clinic Charlotte North Carolina 28204
University of Tennessee Cancer Institute Memphis Tennessee 38104
Virginia Commonwealth University Richmond Virginia 23298-0306

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01179217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 18, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01179217 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →